Endpoints News 2026-03-03 FDA explains how some copycat drugs can still win three years of exclusivity
Endpoints News 2026-03-03 EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway
Endpoints News 2026-03-03 Boehringer Ingelheim tried to use a tempting, tough cancer target for liver disease. It didn’t work
Endpoints News 2026-03-03 Hims partner Strive Pharmacy will reintroduce GLP-1 pill pulled from market
Endpoints News 2026-03-02 United Therapeutics to take pulmonary hypertension drug to FDA for approval
Endpoints News 2026-03-02 Aardvark's stock plummets on study pause; BioNTech heads to Phase 3 with DualityBio ADC
Endpoints News 2026-03-02 Roche gets third pivotal win with MS drug, but liver signal could be a problem
Endpoints News 2026-02-28 Merck looks to expand Welireg label following combo readouts with Keytruda, Lenvima
Endpoints News 2026-02-28 GLP-1 news galore; Top 100 venture investors; Doug Ingram to step down; and more